Lilly to participate in J.P. Morgan Healthcare Conference
Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) will participate in the 44th Annual J.P. Morgan Healthcare Conference, scheduled for Jan. 12-15, 2025. David A. Ricks, Lilly chair and CEO, will appear in a fireside chat on Tuesday, Jan. 13 at 5:15 p.m. ET.
A live audio webcast will be accessible via the company's Webcasts & Presentations investor page and a replay will be available on the same site for approximately 90 days.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, LLY declined 0.74%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
While LLY is up 3.38%, large-cap pharma peers show more modest gains (e.g., ABBV +1.43%, JNJ +1.82%, AZN +1.32%, NVS +0.96%, NVO +0.82%), suggesting relatively stronger name-specific momentum.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 12 | Phase 3 update | Positive | +1.8% | Updated EMBER-3 data reinforced efficacy and OS trends in advanced breast cancer. |
| Dec 11 | Phase 3 obesity data | Positive | +1.6% | TRIUMPH-4 topline showed up to 28.7% weight loss and pain reduction with retatrutide. |
| Dec 09 | New manufacturing site | Positive | -1.5% | Announcement of >$6B Alabama API facility and thousands of new jobs through 2032. |
| Dec 09 | Acquisition step | Positive | -1.5% | Completion of Adverum tender offer with cash plus CVR structure ahead of closing. |
| Dec 09 | Phase 3 oncology data | Positive | -1.5% | Jaypirca reduced progression or death risk by 80% vs chemoimmunotherapy in CLL/SLL. |
Recent history shows mixed alignment: strong positive clinical and strategic news often saw negative next-day moves, while some positive trial updates were rewarded, indicating inconsistent reactions to good news.
Over the past week, LLY has reported multiple positive developments, including favorable Phase 3 data for Inluriyo™ and retatrutide, a planned >$6 billion API facility in Alabama, the completion of the Adverum tender offer, and strong Phase 3 data for Jaypirca®. Price reactions were positive for the December 11 and 12 clinical updates but negative (around -1.5%) for the Alabama facility, Adverum acquisition step, and Jaypirca data, showing that strong fundamentals have not always translated into immediate gains.
Market Pulse Summary
This announcement highlights LLY’s participation in a major healthcare conference, including a CEO fireside chat and a webcast replay available for about 90 days. Set against recent positive Phase 3 updates and strategic investments, the event offers another venue for management to discuss its pipeline and expansion plans. Investors may watch for any new disclosures or clarified timelines relative to recent trial results and manufacturing build-out.
AI-generated analysis. Not financial advice.
A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's investor website at https://investor.lilly.com/webcasts-and-presentations. A replay of the presentation will be available on this same website for approximately 90 days.
About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. F-LLY
Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are references in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.
Refer to: | Ashley Hennessey; gentry_ashley_jo@lilly.com; 317-416-4363 (Media) |
Michael Czapar; czapar_michael_c@lilly.com; 317-617-0983 (Investors) |
View original content to download multimedia:https://www.prnewswire.com/news-releases/lilly-to-participate-in-jp-morgan-healthcare-conference-302640506.html
SOURCE Eli Lilly and Company
FAQ
When will Eli Lilly (LLY) present at the J.P. Morgan Healthcare Conference in 2025?
What time is David A. Ricks’ fireside chat for LLY at J.P. Morgan?
How can investors listen to Lilly’s (LLY) presentation at the conference?
Will there be a replay of Eli Lilly’s (LLY) J.P. Morgan presentation and for how long?
Where is the Lilly (LLY) webcast hosted for the J.P. Morgan Healthcare Conference?
Who from Lilly (LLY) is scheduled to speak at the 44th J.P. Morgan Healthcare Conference?
